Which oMeds pathway helps with persistent fatigue?
Persistent fatigue is routed by candidacy. Men with low total/free testosterone are routed to TRT; women in peri/menopause to BHRT; mitochondrial or longevity-axis fatigue to NAD+. The biomarker panel decides — not the symptom alone.
Full answer
Fatigue is a routing signal, not a diagnosis. The oMeds Assessment screens for the three most common reversible drivers — low testosterone, perimenopausal hormone shifts, and cellular/mitochondrial decline — and routes to the matching pathway only after a provider-reviewed biomarker panel. Men with confirmed low total and free testosterone, normal hematocrit, and acceptable cardiovascular candidacy are routed to Testosterone Optimization (TRT). Women with cycle-phase or menopausal hormone shifts and matching biomarker context are routed to BHRT. Patients with documented age-related cellular decline, recovery debt, or longevity-axis goals are routed to NAD+. Thyroid, iron, B12, and vitamin D are screened first because their correction often resolves fatigue without further pathway escalation. Every route is synchronous-video provider-reviewed and re-read at the recalibration window.
Educational. Not a substitute for individualized provider review.
- Testosterone Optimization pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29